JPH06287594A - Production of triglyceride containing docosahexaenoic acid - Google Patents
Production of triglyceride containing docosahexaenoic acidInfo
- Publication number
- JPH06287594A JPH06287594A JP5097208A JP9720893A JPH06287594A JP H06287594 A JPH06287594 A JP H06287594A JP 5097208 A JP5097208 A JP 5097208A JP 9720893 A JP9720893 A JP 9720893A JP H06287594 A JPH06287594 A JP H06287594A
- Authority
- JP
- Japan
- Prior art keywords
- triglyceride
- fatty acid
- acid
- docosahexaenoic acid
- dha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 title claims abstract description 67
- 235000020669 docosahexaenoic acid Nutrition 0.000 title claims abstract description 52
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229940090949 docosahexaenoic acid Drugs 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 44
- 229930195729 fatty acid Natural products 0.000 claims abstract description 44
- 239000000194 fatty acid Substances 0.000 claims abstract description 44
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 40
- 235000019197 fats Nutrition 0.000 claims abstract description 13
- 108090001060 Lipase Proteins 0.000 claims abstract description 11
- 239000004367 Lipase Substances 0.000 claims abstract description 11
- 102000004882 Lipase Human genes 0.000 claims abstract description 11
- 235000019421 lipase Nutrition 0.000 claims abstract description 11
- 125000005457 triglyceride group Chemical group 0.000 claims abstract description 10
- 235000019198 oils Nutrition 0.000 claims description 16
- 239000000470 constituent Substances 0.000 claims description 11
- 235000021323 fish oil Nutrition 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- 238000013375 chromatographic separation Methods 0.000 claims description 4
- -1 fatty acid ester Chemical class 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 238000005809 transesterification reaction Methods 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 6
- 150000002148 esters Chemical class 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 239000000463 material Substances 0.000 abstract 2
- 239000007858 starting material Substances 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 239000003921 oil Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000003925 fat Substances 0.000 description 10
- 229940040461 lipase Drugs 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- 108010048733 Lipozyme Proteins 0.000 description 2
- 241001125048 Sardina Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000962514 Alosa chrysochloris Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000303962 Rhizopus delemar Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- SKSLQVWNRUWRAQ-UHFFFAOYSA-N icosa-1,3,5,7,9-pentaene Chemical compound CCCCCCCCCCC=CC=CC=CC=CC=C SKSLQVWNRUWRAQ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000004702 methyl esters Chemical group 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Fats And Perfumes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、構成脂肪酸として1,
3位に任意に選択される1種類の脂肪酸を含有し、かつ
2位にドコサヘキサエン酸を含有しているトリグリセリ
ドを製造する方法に関する。BACKGROUND OF THE INVENTION The present invention relates to
The present invention relates to a method for producing a triglyceride containing one kind of arbitrarily selected fatty acid at the 3-position and docosahexaenoic acid at the 2-position.
【0002】[0002]
【従来の技術】近年、ドコサヘキサエン酸(以下、DH
Aと略記する)には、学習機能向上作用、制癌作用、あ
るいは血中脂質低下作用など多くの生理活性を有するこ
とが明かになりつつある。ヒトにおいては、脳灰白質
部、網膜、神経、心臓、精子、母乳などにDHAが多く
含まれている。そして、老齢になるにつれて脳内のDH
A含量が減少することなどから、神経系において何らか
の重要な役割を担っていると推測されている。そこで、
乳幼児食、特に未熟児用の食品にはDHAの添加が必要
であると考えられている。また、食品へDHAを添加す
ることにより、高年齢層の脳機能向上に役立つとの期待
も持たれるに至っている。2. Description of the Related Art Recently, docosahexaenoic acid (hereinafter referred to as DH
It is becoming clear that it has many physiological activities such as a learning function improving effect, a carcinostatic effect, or a blood lipid lowering effect. In humans, a large amount of DHA is contained in brain gray matter, retina, nerves, heart, sperm, breast milk and the like. And as we get older, DH in the brain
It is presumed that it plays an important role in the nervous system because the A content decreases. Therefore,
It is considered necessary to add DHA to infant foods, especially foods for premature babies. In addition, it has been expected that the addition of DHA to foods will help improve brain function in the elderly.
【0003】海産魚の魚油中には、多くのDHAが含有
されていることが知られている。また、エイコサペンタ
エン酸(以下、EPAと略記する)やDHAなどの高度
不飽和脂肪酸は、イワシ油をはじめとする魚油、あるい
は高度不飽和脂肪酸生成微生物から分離、精製されてい
る。特にDHAの場合、DHAを産生する微生物は見出
されておらず、価格やイメージの面から魚油の使用が重
要視されている。そこで、複雑な脂肪酸組成を有する魚
油からDHAを選択的に分離、精製する方法が種々試み
られている。魚油から高度不飽和脂肪酸を分離、精製す
るに際しては、その複雑な脂肪酸構成のために、予め化
学的な処理あるいは酵素的な処理を行う必要があると考
えられる。通常、化学的な方法あるいは酵素的な方法に
より魚油を加水分解し、遊離脂肪酸あるいはエステル化
物として得られるDHAを尿素付加法、塩形成法、超臨
界二酸化炭素抽出法、カラムクロマトグラフィーなどに
供することでDHAの精製を行っている。なお、酵素的
な方法は化学的な方法に比べて温和な条件で処理するこ
とができるので、不安定な高度不飽和脂肪酸を含有する
油脂の前処理としては、酵素的な方法を行うことが好ま
しいと考えられ、酵素の基質特異性あるいは位置特異性
を利用してDHAを得る方法として、Candida
cylidracea由来のリパーゼを用いて選択的に
加水分解を行う方法(特開昭58−165796号公
報、特開平3−19693号公報)などが提案されてい
る。It is known that a large amount of DHA is contained in fish oil of marine fish. Further, highly unsaturated fatty acids such as eicosapentaenoic acid (hereinafter abbreviated as EPA) and DHA have been separated and purified from fish oils such as sardine oil or highly unsaturated fatty acid-producing microorganisms. In particular, in the case of DHA, no microorganism that produces DHA has been found, and the use of fish oil is regarded as important in terms of price and image. Therefore, various methods for selectively separating and purifying DHA from fish oil having a complicated fatty acid composition have been tried. When separating and purifying highly unsaturated fatty acids from fish oil, it is considered necessary to carry out chemical treatment or enzymatic treatment in advance because of their complicated fatty acid composition. Usually, DHA obtained by hydrolyzing fish oil by a chemical method or an enzymatic method and obtained as a free fatty acid or an esterified product is subjected to a urea addition method, salt formation method, supercritical carbon dioxide extraction method, column chromatography, etc. Is purifying DHA. Since the enzymatic method can be treated under milder conditions than the chemical method, an enzymatic method can be used as a pretreatment for fats and oils containing unstable highly unsaturated fatty acids. As a method that is considered to be preferable and obtains DHA by utilizing the substrate specificity or regiospecificity of the enzyme, Candida
Methods such as selective hydrolysis using a lipase derived from cylideacea (Japanese Patent Laid-Open Nos. 58-165796 and 3-19693) have been proposed.
【0004】また、グリセリドを低級アルコールのエス
テルにした後、蒸留や尿素包接処理して濃縮分離を行う
方法(特開昭58−8037号公報)、逆相クロマトグ
ラフィーを用いる方法(特開58−88339号公報、
特開昭58−109444号公報)などが知られている
が、酸化安定性が弱く極めて不安定な物質であるため多
段階の工程が必要であり、精製に多大なコストもかかる
という問題があり、供給量は十分ではない。その結果、
実際にはDHAのエチルエステルが医薬品として上市さ
れているに過ぎない。一般に、エチルエステル体やメチ
ルエステル体の油脂はトリグリセリド体と比較して、小
腸での消化吸収性において劣るといわれている。したが
って、医薬品分野や食品分野においては、トリグリセリ
ドの形態でのDHAの供給が強く望まれている。特に、
食品分野でDHAを利用するためには、トリグリセリド
の形態のDHAを安価に、かつ大量に供給する必要があ
るので、効率が良く、しかも酸化安定性を考慮したDH
Aの製造法の開発が望まれていた。Further, a method in which a glyceride is converted to an ester of a lower alcohol and then subjected to a distillation or urea inclusion treatment for concentration and separation (JP-A-58-8037) and a method using reverse phase chromatography (JP-A-58). -88339 publication,
Japanese Unexamined Patent Publication (Kokai) No. 58-109444) is known, but it has a problem that it requires a multi-step process because it is a substance having weak oxidation stability and is extremely unstable, and that it requires a great deal of cost for purification. , The supply is not enough. as a result,
Actually, DHA ethyl ester is only marketed as a drug. Generally, it is said that the fats and oils of ethyl ester form and methyl ester form are inferior in digestive absorbability in the small intestine as compared with triglyceride form. Therefore, supply of DHA in the form of triglyceride is strongly desired in the pharmaceutical field and food field. In particular,
In order to use DHA in the food field, it is necessary to inexpensively supply a large amount of DHA in the form of triglyceride. Therefore, DH that is efficient and has oxidative stability taken into consideration.
Development of the manufacturing method of A was desired.
【0005】[0005]
【発明が解決しようとする課題】本発明者らは、魚油か
らDHA含量の高い油脂を分離する方法について、鋭意
検討を行ったところ、トリグリセリドの1,3位に特異
的に作用するリパーゼのエステル交換反応で、構成脂肪
酸として2位に高度不飽和脂肪酸を含有し、1,3位に
任意に選択された1種類の脂肪酸を含有するトリグリセ
リドを生成させることにより、通常の分離、精製方法で
容易にDHA含量の高いトリグリセリドを得ることがで
きることを見出し、本発明を成すに至った。したがっ
て、本発明は、構成脂肪酸として2位にDHAを含有
し、かつ1,3位に任意に選択される1種類の脂肪酸を
含有しているトリグリセリドを製造する方法を提供する
ことを課題とする。DISCLOSURE OF THE INVENTION The inventors of the present invention have made extensive studies as to a method for separating fats and oils having a high DHA content from fish oil. As a result, an ester of lipase which specifically acts on the 1,3-positions of triglycerides. By the exchange reaction, a triglyceride containing a polyunsaturated fatty acid at the 2-position as a constituent fatty acid and one kind of arbitrarily selected fatty acid at the 1- and 3-positions is produced, thereby facilitating an ordinary separation and purification method. It was found that triglycerides having a high DHA content can be obtained and the present invention has been completed. Therefore, it is an object of the present invention to provide a method for producing a triglyceride containing DHA at the 2-position as a constituent fatty acid and one kind of fatty acid arbitrarily selected at the 1- and 3-positions. .
【0006】[0006]
【課題を解決するための手段】以下、本発明のDHA含
有トリグリセリドの製造法について説明する。本発明で
原料として用いることのできる構成脂肪酸としてトリグ
リセリドの2位にDHAを含有している油脂としては、
DHAが2位に結合しているトリグリセリドであれば、
その含量も含めて、どのような種類の油脂でも用いるこ
とができ、例えば、DHA含量が10%未満の油脂であ
っても構わない。また、トリグリセリドとして純粋であ
れば前段階での更なる精製処理は必要ではない。但し、
2位のDHA含量が少ない油脂ほど処理に時間を要する
ので原料として用いることは不利である。The method for producing the DHA-containing triglyceride of the present invention will be described below. Examples of fats and oils containing DHA at the 2-position of triglyceride as a constituent fatty acid that can be used as a raw material in the present invention are:
If DHA is a triglyceride linked to the 2-position,
Any kind of fats and oils including the content thereof can be used, and for example, fats and oils having a DHA content of less than 10% may be used. Further, if the triglyceride is pure, no further purification treatment in the previous step is necessary. However,
It is disadvantageous to use as a raw material because the oil and fat having a lower second-order DHA content requires longer processing time.
【0007】また、任意に選択される1種類の脂肪酸あ
るいは脂肪酸エステルとしては、ミリスチン酸、パルミ
チン酸、ステアリン酸などの飽和酸やオレイン酸、リノ
ール酸、EPA、DHAなどの不飽和酸、あるいは、そ
れらの脂肪酸とエチルアルコールやメチルアルコールと
のエステルなどを例示することができる。さらには、高
オレイン酸含有油であるオリーブ油などの加水分解物や
ケン化物なども用いることができる。As one kind of arbitrarily selected fatty acid or fatty acid ester, saturated acids such as myristic acid, palmitic acid and stearic acid and unsaturated acids such as oleic acid, linoleic acid, EPA and DHA, or Examples thereof include esters of those fatty acids with ethyl alcohol and methyl alcohol. Further, a hydrolyzate such as olive oil which is a high oleic acid-containing oil, a saponified product and the like can also be used.
【0008】本発明では、まず、構成脂肪酸としてトリ
グリセリドの2位にDHAを含有している油脂と、任意
に選択される1種類の脂肪酸あるいは脂肪酸エステルと
を原料とし、1,3位に特異的に作用するリパーゼを作
用させることによりエステル交換反応を行って、構成脂
肪酸として2位にDHAを含有し、かつ1,3位に任意
に選択される1種類の脂肪酸を含有しているトリグリセ
リドを生成させる。なお、本発明で用いることのできる
1,3位に特異的に作用するリパーゼとしては、ブタ膵
臓リパーゼやRhizopus属、Aspergill
us属などの微生物が生産するものを例示することがで
きる。これらのリパーゼの使用形態については、特に限
定されるものではないが、固定化酵素あるいは化学修飾
酵素を用いることが望ましい。リパーゼの使用量は、反
応条件や用いる原料油脂の性質により適宜決定すれば良
く、特に制限されるものではない。In the present invention, first, an oil or fat containing DHA at the 2-position of triglyceride as a constituent fatty acid and one kind of arbitrarily selected fatty acid or fatty acid ester are used as raw materials, and the specific fatty acids at the 1- and 3-positions are specified. By carrying out a transesterification reaction by acting on a lipase that acts on to produce a triglyceride containing DHA at the 2-position as a constituent fatty acid and one kind of arbitrarily selected fatty acid at the 1- and 3-positions Let Examples of the lipase that can be used in the present invention that specifically acts at the 1- and 3-positions include porcine pancreatic lipase, Rhizopus genus, and Aspergill.
Those produced by microorganisms such as genus us can be exemplified. The use form of these lipases is not particularly limited, but it is desirable to use an immobilized enzyme or a chemically modified enzyme. The amount of lipase used may be appropriately determined depending on the reaction conditions and the properties of the raw material fat or oil used, and is not particularly limited.
【0009】本発明は、特に、DHAが構成脂肪酸とし
て魚油中のトリグリセリドの2位に集中していることを
利用したものであって、トリグリセリドの1,3位に特
異的に作用するリパーゼを用い、トリグリセリドの2位
にDHAを残したまま1,3位の脂肪酸のみを置換し、
構成脂肪酸として2位にDHAを含有し、かつ1,3位
に任意に選択される1種類の脂肪酸を含有しているトリ
グリセリドを生成させる。つまり、トリグリセリドと脂
肪酸とのアシドリシス反応、あるいはトリグリセリドと
低級アルコール脂肪酸エステルとのエステル交換反応に
より、油脂中の1,3位の脂肪酸が任意に選択された1
種類の脂肪酸と置換される。なお、生成した遊離脂肪
酸、遊離脂肪酸エステル、モノグリセリド、ジグリセリ
ドなどは、アルカリ洗浄、水蒸気蒸留、分子蒸留、溶剤
抽出などの処理を行うことにより除去することができ
る。このようにして、トリグリセリドの2位のDHAを
残したまま、魚油の複雑な脂肪酸構成よりなる多くの分
子種を整理し、単純化することができる。The present invention particularly utilizes the fact that DHA is concentrated as a constituent fatty acid at the 2-position of triglyceride in fish oil, and uses a lipase that specifically acts at the 1- and 3-positions of triglyceride. , Replacing only the fatty acids at positions 1 and 3 while leaving DHA at position 2 of triglyceride,
A triglyceride containing DHA at the 2-position as a constituent fatty acid and one kind of arbitrarily selected fatty acid at the 1- and 3-positions is produced. That is, the fatty acid at the 1- and 3-positions in the fat or oil is arbitrarily selected by an acidolysis reaction between triglyceride and fatty acid or a transesterification reaction between triglyceride and lower alcohol fatty acid ester.
It is replaced with a different type of fatty acid. The produced free fatty acid, free fatty acid ester, monoglyceride, diglyceride and the like can be removed by performing treatments such as alkali washing, steam distillation, molecular distillation and solvent extraction. In this way, many molecular species consisting of the complex fatty acid composition of fish oil can be arranged and simplified while leaving the 2-position DHA of triglyceride.
【0010】次に、このようにして得られる1,3位に
任意に選択される1種類の脂肪酸を含有しているトリグ
リセリドから、構成脂肪酸として2位にDHAを含有
し、かつ1,3位に任意に選択される1種類の脂肪酸を
含有しているトリグリセリドを分離する。この分離に
は、通常、行われている晶析、抽出、吸着、クロマトグ
ラフィー、膜分離などの技術を用いることが可能である
が、作業効率などを考えるとクロマトグラフィーを用い
ることが有利である。従来より行われているカラムクロ
マトグラフィーには、回分式、循環式、移動床式、擬似
移動床式など幾つかの操作形式が知られているが、特に
擬似移動床式クロマト分離装置(SMB)を用いること
が好ましい。Next, from the triglyceride containing one kind of fatty acid arbitrarily selected in the 1,3-position thus obtained, DHA is contained in the 2-position as a constituent fatty acid, and the 1,3-position is contained. A triglyceride containing one kind of fatty acid arbitrarily selected in is separated. For this separation, it is possible to use techniques such as crystallization, extraction, adsorption, chromatography and membrane separation which are usually performed, but it is advantageous to use chromatography in view of work efficiency and the like. . There are several known operation modes such as a batch type, a circulation type, a moving bed type, and a simulated moving bed type in the column chromatography which has been conventionally performed, but in particular, a simulated moving bed type chromatographic separation device (SMB) is used. Is preferably used.
【0011】例えば、魚油とオレイン酸とを原料として
用いた場合、まず、生成した1,3位にオレイン酸を含
有しているトリグリセリドから、カラムクロマトグラフ
ィーにより、1,3−ジオレオ−2−エイコサペンタエ
ン及び1,3−ジオレオ−2−ドコサヘキサエンの2種
のトリグリセリドを分離する。そして、この2種類のト
リグリセリドを擬似移動床式クロマト分離装置で精製す
ることができる。このようにして得られたトリグリセリ
ドは、33%のDHAを含有することとなる。For example, when fish oil and oleic acid are used as raw materials, first, from the produced triglyceride containing oleic acid at the 1,3-positions, 1,3-dioleo-2-e is subjected to column chromatography. Two triglycerides, icosapentaene and 1,3-dioleo-2-docosahexaene, are separated. Then, these two types of triglycerides can be purified by a simulated moving bed chromatographic separation device. The triglyceride thus obtained will contain 33% DHA.
【0012】なお、疑似移動床クロマト分離装置の溶出
条件を変えることにより、EPAなどの高度不飽和脂肪
酸を2位に含有するトリグセリドを含む組成物を調製す
ることができるので、必要に応じてDHA/EPA比を
制御したトリグリセリドを提供することも可能である。
また、原料として用いる脂肪酸を適宜選択することによ
り、飽和脂肪酸(S)/不飽和脂肪酸(U)比やn−3
系脂肪酸/n−6系脂肪酸比を自在に制御することもで
きる。次に本発明の実施例を挙げて具体的に説明する。By changing the elution conditions of the simulated moving bed chromatographic separation device, a composition containing triglyceride containing a highly unsaturated fatty acid such as EPA at the 2-position can be prepared. It is also possible to provide triglycerides with a controlled / EPA ratio.
Further, by appropriately selecting the fatty acid used as the raw material, the saturated fatty acid (S) / unsaturated fatty acid (U) ratio or n-3
The system fatty acid / n-6 system fatty acid ratio can also be freely controlled. Next, an example of the present invention will be specifically described.
【0013】[0013]
【実施例1】イワシ油(DHA含量6.51%)100
gとオレイン酸(純度95%)1,000gとを原料と
し、Rhizopus delemar由来のリパーゼ
を脂肪酸で化学修飾したリパーゼ40gを用いて、n−
ヘキサン中で、40℃、24時間酵素反応を行った。反
応終了後、エタノール:水(9:1)の溶媒を用いて脂
肪酸を抽出し、生成したトリグリセリド80g(DHA
含量5.48%)を得た。このトリグリセリドを12.
5g/l濃度でアセトン:アセトニトリル(1:1)の
溶媒に溶解した後、ODS−AM120−S50(YM
C社製)を充填したカラム(直径25mm、長さ460
mm)で精製を行い、1,3−ジオレオ−2−エイコサ
ペンタエン及び1,3−ジオレオ−2−ドコサヘキサエ
ンを含む画分をUV206nm及びガスクロマトグラフ
ィーで確認して回収した。次に、1,3−ジオレオ−2
−エイコサペンタエン及び1,3−ジオレオ−2−ドコ
サヘキサエンを含む画分12gを12.5g/l濃度で
アセトン:アセトニトリル(2:1)の溶媒に溶解し、
SMB処理液とした。SMBは、カラムの直径25mm
長さ460mmの8塔型で、各々ODS−AM120−
S50(YMC社製)を充填し、移動相としてアセト
ン:アセトニトリル(1:1)の溶媒を用いた。SMB
の運転条件は、処理液供給量0.89ml/分、溶離液
供給量2.53ml/分、エキストラクト抜き出し量
1.71ml/分、ラフィネート抜き出し量1.71m
l/分とし、カラム温度40℃、ステップ時間114.
89分とした。その結果、エキストラクトに目的画分
1,844mlを得た。このエキストラクトを濃縮乾固
して1,3−ジオレオ−2−ドコサヘキサエン5.4g
(純度92.3%)を得た。Example 1 Sardine oil (DHA content 6.51%) 100
g and oleic acid (purity 95%) 1,000 g as raw materials, and using lipase 40 g obtained by chemically modifying lipase derived from Rhizopus delemar with fatty acid, n-
The enzymatic reaction was carried out in hexane at 40 ° C. for 24 hours. After completion of the reaction, 80 g of triglyceride produced by extracting fatty acid using a solvent of ethanol: water (9: 1) (DHA
Content 5.48%) was obtained. 12. Add this triglyceride
After dissolving in a solvent of acetone: acetonitrile (1: 1) at a concentration of 5 g / l, ODS-AM120-S50 (YM
Column (diameter 25 mm, length 460) packed with C company
mm), and a fraction containing 1,3-dioleo-2-eicosapentaene and 1,3-dioleo-2-docosahexaene was confirmed by UV 206 nm and gas chromatography and collected. Next, 1,3-dioleo-2
12 g of a fraction containing eicosapentaene and 1,3-dioleo-2-docosahexaene was dissolved in a solvent of acetone: acetonitrile (2: 1) at a concentration of 12.5 g / l,
This was the SMB treatment liquid. SMB has a column diameter of 25 mm
Eight towers with a length of 460 mm, each with ODS-AM120-
S50 (manufactured by YMC) was filled, and a solvent of acetone: acetonitrile (1: 1) was used as a mobile phase. SMB
The operating conditions were as follows: processing solution supply rate 0.89 ml / min, eluent supply rate 2.53 ml / min, extract withdrawal rate 1.71 ml / min, raffinate withdrawal rate 1.71 m.
1 / min, column temperature 40 ° C., step time 114.
It was 89 minutes. As a result, 1844 ml of the target fraction was obtained in the extract. This extract was concentrated to dryness to give 5.4 g of 1,3-dioleo-2-docosahexaene.
(Purity 92.3%) was obtained.
【0014】[0014]
【実施例2】カツオ油(DHA含量7.91%)500
gとオレイン酸(純度95%)600gを原料とし、M
ucor miehei由来の固定化酵素リポザイム
(ノボ社製)60gを用いて、n−ヘキサン中で、60
℃、6時間酵素反応を行った。反応終了後、リポザイム
を濾別し、アルカリ脱酸法で脂肪酸部分を除去して、生
成したトリグリセリド432g(DHA含量11.20
%)を得た。このトリグリセリドを12.5g/l濃度
でアセトン:アセトニトリル(1:1)の溶媒に溶解し
た後、ODS−AM120−S50(YMC社製)を充
填したカラム(直径25mm、長さ460mm)で精製
を行い、1,3−ジオレオ−2−エイコサペンタエン及
び1,3−ジオレオ−2−ドコサヘキサエンを含む画分
をUV206nm及びガスクロマトグラフィーで確認し
て回収した。次に、1,3−ジオレオ−2−エイコサペ
ンタエン及び1,3−ジオレオ−2−ドコサヘキサエン
を含む画分86.4gを12.5g/l濃度でアセト
ン:アセトニトリル(2:1)の溶媒に溶解し、SMB
処理液とした。SMBは、カラムの直径25mm長さ4
60mmの8塔型で、各々ODS−AM120−S50
(YMC社製)を充填し、移動相としてアセトン:アセ
トニトリル(2:1)の溶媒を用いた。SMBの運転条
件は、処理液供給量0.89ml/分、溶離液供給量
2.53ml/分、エキストラクト抜き出し量1.71
ml/分、ラフィネート抜き出し量1.71ml/分と
し、カラム温度40℃、ステップ時間60.84分とし
た。その結果、エキストラクトに目的画分13,280
mlを得た。このエキストラクトを濃縮乾固して1,3
−ジオレオ−2−ドコサヘキサエン40.1g(純度9
5.1%)を得た。Example 2 Skipjack oil (DHA content 7.91%) 500
g and oleic acid (purity 95%) as raw materials, M
Ucor miehei- derived immobilized enzyme lipozyme (manufactured by Novo Co., Ltd.) 60 g was used in n-hexane to prepare 60
The enzyme reaction was performed at 6 ° C for 6 hours. After the reaction was completed, the lipozyme was filtered off, the fatty acid portion was removed by the alkaline deoxidation method, and 432 g of the produced triglyceride (DHA content 11.20) was obtained.
%) Was obtained. This triglyceride was dissolved in a solvent of acetone: acetonitrile (1: 1) at a concentration of 12.5 g / l, and then purified with a column (diameter 25 mm, length 460 mm) packed with ODS-AM120-S50 (YMC). The fraction containing 1,3-dioleo-2-eicosapentaene and 1,3-dioleo-2-docosahexaene was confirmed by UV 206 nm and gas chromatography and collected. Next, 86.4 g of a fraction containing 1,3-dioleo-2-eicosapentaene and 1,3-dioleo-2-docosahexaene was dissolved in a solvent of acetone: acetonitrile (2: 1) at a concentration of 12.5 g / l. And SMB
It was used as a treatment liquid. SMB has a column diameter of 25 mm and a length of 4
60mm 8 tower type, ODS-AM120-S50
(Manufactured by YMC) was filled, and a solvent of acetone: acetonitrile (2: 1) was used as a mobile phase. The operating conditions of the SMB are as follows: processing liquid supply rate 0.89 ml / min, eluent supply amount 2.53 ml / min, extract withdrawal amount 1.71.
The raffinate withdrawal rate was 1.71 ml / min, the column temperature was 40 ° C., and the step time was 60.84 minutes. As a result, the target fraction 13,280 was added to the extract.
ml was obtained. Concentrate and dry this extract to 1,3
-Dioleo-2-docosahexaene 40.1 g (purity 9
5.1%) was obtained.
【0015】[0015]
【発明の効果】本発明の方法により、魚油などのDHA
を高度に含有する油脂から、医薬及び食品の素材として
有用なDHA含有トリグリセリドを容易に分離、回収す
ることができる。INDUSTRIAL APPLICABILITY By the method of the present invention, DHA such as fish oil
DHA-containing triglyceride useful as a raw material for medicines and foods can be easily separated and recovered from oils and fats containing a large amount of.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 (C12P 7/64 C12R 1:785) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location (C12P 7/64 C12R 1: 785)
Claims (4)
にドコサヘキサエン酸を含有している油脂と、任意に選
択される1種類の脂肪酸あるいは脂肪酸エステルとを原
料とし、トリグリセリドの1,3位に特異的に作用する
リパーゼを作用させてエステル交換反応を行わせ、構成
脂肪酸として2位にドコサヘキサエン酸を含有し、かつ
1,3位に任意に選択される1種類の脂肪酸を含有して
いるトリグリセリドを生成させた後、これを採取するこ
とを特徴とするドコサヘキサエン酸含有トリグリセリド
の製造法。1. An oil or fat containing docosahexaenoic acid at the 2-position of triglyceride as a constituent fatty acid and one kind of arbitrarily selected fatty acid or fatty acid ester are used as raw materials, and specifically at the 1- and 3-positions of triglyceride. A transesterification reaction is carried out by acting a lipase which acts to form a triglyceride containing docosahexaenoic acid at the 2-position as a constituent fatty acid and one kind of arbitrarily selected fatty acid at the 1- and 3-positions. And a docosahexaenoic acid-containing triglyceride.
にドコサヘキサエン酸を含有している油脂が、魚油であ
る請求項1に記載のドコサヘキサエン酸含有トリグリセ
リドの製造法。2. The method for producing a glyceride containing docosahexaenoic acid according to claim 1, wherein the fat or oil containing docosahexaenoic acid at the 2-position of the triglyceride as a constituent fatty acid is fish oil.
レイン酸である請求項1または2に記載のドコサヘキサ
エン酸含有トリグリセリドの製造法。3. The method for producing a docosahexaenoic acid-containing triglyceride according to claim 1 or 2, wherein one kind of arbitrarily selected fatty acid is oleic acid.
の採取を擬似移動床式クロマト分離装置で行う請求項1
乃至3のいずれかに記載のドコサヘキサエン酸含有トリ
グリセリドの製造法。4. The simulated moving bed chromatographic separation device collects the glyceride containing docosahexaenoic acid.
5. The method for producing a triglyceride containing docosahexaenoic acid according to any one of 3 to 3.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP09720893A JP3340182B2 (en) | 1993-03-31 | 1993-03-31 | Method for producing triglyceride containing docosahexaenoic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP09720893A JP3340182B2 (en) | 1993-03-31 | 1993-03-31 | Method for producing triglyceride containing docosahexaenoic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06287594A true JPH06287594A (en) | 1994-10-11 |
JP3340182B2 JP3340182B2 (en) | 2002-11-05 |
Family
ID=14186210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09720893A Expired - Fee Related JP3340182B2 (en) | 1993-03-31 | 1993-03-31 | Method for producing triglyceride containing docosahexaenoic acid |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3340182B2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248909B1 (en) | 1998-06-19 | 2001-06-19 | Suntory Limited | Triglyceride and composition comprising the same |
WO2013005047A1 (en) * | 2011-07-06 | 2013-01-10 | Basf Pharma (Callanish) Limited | Heated chromatographic separation process |
US9150816B2 (en) | 2013-12-11 | 2015-10-06 | Novasep Process Sas | Chromatographic method for the production of polyunsaturated fatty acids |
US9321715B2 (en) | 2009-12-30 | 2016-04-26 | Basf Pharma (Callanish) Limited | Simulated moving bed chromatographic separation process |
US9428711B2 (en) | 2013-05-07 | 2016-08-30 | Groupe Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
US9694302B2 (en) | 2013-01-09 | 2017-07-04 | Basf Pharma (Callanish) Limited | Multi-step separation process |
US9695382B2 (en) | 2011-07-06 | 2017-07-04 | Basf Pharma (Callanish) Limited | SMB process for producing highly pure EPA from fish oil |
US10975031B2 (en) | 2014-01-07 | 2021-04-13 | Novasep Process | Method for purifying aromatic amino acids |
-
1993
- 1993-03-31 JP JP09720893A patent/JP3340182B2/en not_active Expired - Fee Related
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248909B1 (en) | 1998-06-19 | 2001-06-19 | Suntory Limited | Triglyceride and composition comprising the same |
US9790162B2 (en) | 2009-12-30 | 2017-10-17 | Basf Pharma (Callanish) Limited | Simulated moving bed chromatographic separation process |
US9321715B2 (en) | 2009-12-30 | 2016-04-26 | Basf Pharma (Callanish) Limited | Simulated moving bed chromatographic separation process |
WO2013005047A1 (en) * | 2011-07-06 | 2013-01-10 | Basf Pharma (Callanish) Limited | Heated chromatographic separation process |
US20140107359A1 (en) * | 2011-07-06 | 2014-04-17 | BASF Pharma(Callanish)Limited | Heated Chromatographic Separation Process |
CN103826715A (en) * | 2011-07-06 | 2014-05-28 | 巴斯夫制药(卡兰尼什)公司 | Heated chromatographic separation process |
EP3906983A1 (en) * | 2011-07-06 | 2021-11-10 | BASF Pharma (Callanish) Limited | Heated chromatographic separation process |
US9347020B2 (en) * | 2011-07-06 | 2016-05-24 | Basf Pharma Callanish Limited | Heated chromatographic separation process |
EP3238800A1 (en) * | 2011-07-06 | 2017-11-01 | BASF Pharma (Callanish) Limited | Heated chromatographic separation process |
US9695382B2 (en) | 2011-07-06 | 2017-07-04 | Basf Pharma (Callanish) Limited | SMB process for producing highly pure EPA from fish oil |
US9771542B2 (en) | 2011-07-06 | 2017-09-26 | Basf Pharma Callanish Ltd. | Heated chromatographic separation process |
US9694302B2 (en) | 2013-01-09 | 2017-07-04 | Basf Pharma (Callanish) Limited | Multi-step separation process |
US10179759B2 (en) | 2013-01-09 | 2019-01-15 | Basf Pharma (Callanish) Limited | Multi-step separation process |
US10214475B2 (en) | 2013-01-09 | 2019-02-26 | Basf Pharma (Callanish) Limited | Multi-step separation process |
JP2019207234A (en) * | 2013-01-09 | 2019-12-05 | バスフ ファーマ(カラニッシュ)リミテッド | Multi-step separation process |
US10723973B2 (en) | 2013-01-09 | 2020-07-28 | Basf Pharma (Callanish) Limited | Multi-step separation process |
US9428711B2 (en) | 2013-05-07 | 2016-08-30 | Groupe Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
US9150816B2 (en) | 2013-12-11 | 2015-10-06 | Novasep Process Sas | Chromatographic method for the production of polyunsaturated fatty acids |
US10975031B2 (en) | 2014-01-07 | 2021-04-13 | Novasep Process | Method for purifying aromatic amino acids |
Also Published As
Publication number | Publication date |
---|---|
JP3340182B2 (en) | 2002-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4236128B2 (en) | Essential oil composition | |
Shahidi et al. | Omega-3 fatty acid concentrates: nutritional aspects and production technologies | |
AU757203B2 (en) | Lipase-catalysed esterification of marine oil | |
EP0784694A1 (en) | Enzymatic methods for polyunsaturated fatty acid enrichment | |
Linder et al. | Enrichment of salmon oil with n‐3 PUFA by lipolysis, filtration and enzymatic re‐esterification | |
JP2003500082A (en) | Concentration and purification of polyunsaturated fatty acid esters by a combination of distillation-enzymatic transesterification | |
JP3340182B2 (en) | Method for producing triglyceride containing docosahexaenoic acid | |
JP2516860B2 (en) | Method for producing concentrated highly unsaturated fatty acid-containing fats and oils | |
Senanayake | Methods of concentration and purification of omega-3 fatty acids | |
JP4210437B2 (en) | Method for producing sterol fatty acid ester for food | |
JPH08214892A (en) | Production of partial glyceride containing highly unsaturated fatty acid | |
JPH0860181A (en) | Highly unsaturated fatty acid-containing oil and fat | |
JP2545480B2 (en) | Functional food material | |
JP2003024096A (en) | Method for producing sterol fatty acid ester for food | |
JP4310387B2 (en) | Omega-3 highly unsaturated fatty acid-containing partial glyceride composition and method for producing the same | |
JP6464144B2 (en) | Method for purifying stearidonic acid | |
JP3853767B2 (en) | Conjugated fatty acid menthol ester and method for producing the same | |
JPH03103499A (en) | Production of highly unsaturated fatty acid monoglyceride | |
JP3734905B2 (en) | Method for purifying omega-3 polyunsaturated fatty acids | |
JP3192411B1 (en) | Method for producing sterol fatty acid ester for food | |
JP7382942B2 (en) | Method for producing glyceride containing docosahexaenoic acid using lipase hydrolysis reaction | |
JP2000342291A (en) | Enzymatic production of glyceride containing highly unsaturated fatty acid | |
JP4578669B2 (en) | Method for producing fats and oils enriched with γ-linolenic acid | |
JP5527983B2 (en) | Process for producing docosahexaenoic acid-rich oil | |
JPH0319694A (en) | Condensation of glyceride of docosahexaenoic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080816 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090816 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100816 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110816 Year of fee payment: 9 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110816 Year of fee payment: 9 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120816 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120816 Year of fee payment: 10 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |